Literature DB >> 8058334

Differential protein binding to the c-myc promoter during differentiation of hematopoietic cell lines.

M Arcinas1, L M Boxer.   

Abstract

In vivo footprinting has been used to examine protein binding sites in the c-myc promoter during differentiation of HL60 and K562 cell lines. The c-myc gene is expressed in proliferating cells, but c-myc levels decrease dramatically during differentiation. A number of potential protein binding sites have been identified from in vitro studies of the c-myc promoter, but very little is known about occupancy of these sites in vivo. We have identified in vivo footprints at DNase hypersensitive sites II2 and III1 which disappear during differentiation, while a footprint at site IV is present only in differentiated cells. Footprints at DNase hypersensitive sites I and II1 do not change with differentiation. A protected region near DNase hypersensitive site III2 is present in both undifferentiated and differentiated cells, but it extends further 5' in undifferentiated cells. From the protected sequences we have been able to identify candidate transcription factors likely to be involved in the control of c-myc expression. By electrophoretic mobility shift assay we have demonstrated that a protein binds to the sequence at site IV. We have also examined the 3' end of the first exon and the 5' end of intron I and do not find any evidence for protein binding sites in this region that was thought to be important for the block to transcription elongation during differentiation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8058334

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Epstein-Barr virus protein can upregulate cyclo-oxygenase-2 expression through association with the suppressor of metastasis Nm23-H1.

Authors:  Rajeev Kaul; Subhash C Verma; Masanao Murakami; Ke Lan; Tathagata Choudhuri; Erle S Robertson
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  Mutational analysis of NM23-H2/NDP kinase identifies the structural domains critical to recognition of a c-myc regulatory element.

Authors:  E H Postel; V H Weiss; J Beneken; A Kirtane
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

3.  Identification of an inducible regulator of c-myb expression during T-cell activation.

Authors:  S C Phan; B Feeley; D Withers; L M Boxer
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

4.  Epstein-Barr virus nuclear antigen 1 interacts with Nm23-H1 in lymphoblastoid cell lines and inhibits its ability to suppress cell migration.

Authors:  Masanao Murakami; Ke Lan; Chitra Subramanian; Erle S Robertson
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

Review 5.  Human NM23/nucleoside diphosphate kinase regulates gene expression through DNA binding to nuclease-hypersensitive transcriptional elements.

Authors:  E H Postel; S J Berberich; J W Rooney; D M Kaetzel
Journal:  J Bioenerg Biomembr       Date:  2000-06       Impact factor: 2.945

6.  NF-kappa B sites function as positive regulators of expression of the translocated c-myc allele in Burkitt's lymphoma.

Authors:  L Ji; M Arcinas; L M Boxer
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

7.  Chromatin fine structure of the c-MYC insulator element/DNase I-hypersensitive site I is not preserved during mitosis.

Authors:  Jun-Ichiro Komura; Hironobu Ikehata; Tetsuya Ono
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-21       Impact factor: 11.205

8.  EBNA3C can modulate the activities of the transcription factor Necdin in association with metastasis suppressor protein Nm23-H1.

Authors:  Rajeev Kaul; Masanao Murakami; Ke Lan; Tathagata Choudhuri; Erle S Robertson
Journal:  J Virol       Date:  2008-12-30       Impact factor: 5.103

9.  Epstein-Barr virus latent nuclear antigens can induce metastasis in a nude mouse model.

Authors:  Rajeev Kaul; Masanao Murakami; Tathagata Choudhuri; Erle S Robertson
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.